Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors

Marco Ragusa, Luisa Statello, Marco Maugeri, Alessandra Majorana, Davide Barbagallo, Loredana Salito, Mariangela Sammito, Manuela Santonocito, Rosario Angelica, Andrea Cavallaro, Marina Scalia, Rosario Caltabiano, Giuseppe Privitera, Antonio Biondi, Maria Di Vita, Alessandro Cappellani, Enrico Vasquez, Salvatore Lanzafame, Elisabetta Tendi, Salvatore Celeste & 3 others Cinzia Di Pietro, Francesco Basile, Michele Purrello

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway has a master control role in various cancer-related biological processes as cell growth, proliferation, differentiation, migration, and apoptosis. It also regulates many transcription factors that control microRNAs (miRNAs) and their biosynthetic machinery. To investigate on the still poorly characterised global involvement of miRNAs within the pathway, we profiled the expression of 745 miRNAs in three colorectal cancer (CRC) cell lines after blocking the pathway with three different inhibitors. This allowed the identification of two classes of post-treatment differentially expressed (DE) miRNAs: (1) common DE miRNAs in all CRC lines after treatment with a specific inhibitor (class A); (2) DE miRNAs in a single CRC line after treatment with all three inhibitors (class B). By determining the molecular targets, biological roles, network position of chosen miRNAs from class A (miR-372, miR-663b, miR-1226*) and class B (miR-92a-1*, miR-135b*, miR-720), we experimentally demonstrated that they are involved in cell proliferation, migration, apoptosis, and globally affect the regulation circuits centred on MAPK/ERK signaling. Interestingly, the levels of miR-92a-1*, miR-135b*, miR-372, miR-720 are significantly higher in biopsies from CRC patients than in normal controls; they also are significantly higher in CRC patients with mutated KRAS than in those with wild-type genotypes (Wilcoxon test, p <0.05): the latter could be a downstream effect of ERK pathway overactivation, triggered by KRAS mutations. Finally, our functional data strongly suggest the following miRNA/target pairs: miR-92a-1*/PTEN-SOCS5; miR-135b*/LATS2; miR-372/TXNIP; miR-663b/CCND2. Altogether, these results contribute to deepen current knowledge on still uncharacterized features of MAPK/ERK pathway, pinpointing new oncomiRs in CRC and allowing their translation into clinical practice and CRC therapy.

Original languageEnglish
Pages (from-to)1421-1438
Number of pages18
JournalJournal of Molecular Medicine
Volume90
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinases
MicroRNAs
Transcriptome
Colorectal Neoplasms
Therapeutics
Cell Proliferation
Apoptosis
Biological Phenomena
Cell Movement
Transcription Factors
Genotype
Biopsy
Cell Line
Mutation
Growth

Keywords

  • Cellular networks
  • Colorectal cancer
  • ERK/MAPK pathway
  • miRNA profile
  • miRNA protein targets

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. / Ragusa, Marco; Statello, Luisa; Maugeri, Marco; Majorana, Alessandra; Barbagallo, Davide; Salito, Loredana; Sammito, Mariangela; Santonocito, Manuela; Angelica, Rosario; Cavallaro, Andrea; Scalia, Marina; Caltabiano, Rosario; Privitera, Giuseppe; Biondi, Antonio; Di Vita, Maria; Cappellani, Alessandro; Vasquez, Enrico; Lanzafame, Salvatore; Tendi, Elisabetta; Celeste, Salvatore; Di Pietro, Cinzia; Basile, Francesco; Purrello, Michele.

In: Journal of Molecular Medicine, Vol. 90, No. 12, 12.2012, p. 1421-1438.

Research output: Contribution to journalArticle

Ragusa, M, Statello, L, Maugeri, M, Majorana, A, Barbagallo, D, Salito, L, Sammito, M, Santonocito, M, Angelica, R, Cavallaro, A, Scalia, M, Caltabiano, R, Privitera, G, Biondi, A, Di Vita, M, Cappellani, A, Vasquez, E, Lanzafame, S, Tendi, E, Celeste, S, Di Pietro, C, Basile, F & Purrello, M 2012, 'Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors', Journal of Molecular Medicine, vol. 90, no. 12, pp. 1421-1438. https://doi.org/10.1007/s00109-012-0918-8
Ragusa, Marco ; Statello, Luisa ; Maugeri, Marco ; Majorana, Alessandra ; Barbagallo, Davide ; Salito, Loredana ; Sammito, Mariangela ; Santonocito, Manuela ; Angelica, Rosario ; Cavallaro, Andrea ; Scalia, Marina ; Caltabiano, Rosario ; Privitera, Giuseppe ; Biondi, Antonio ; Di Vita, Maria ; Cappellani, Alessandro ; Vasquez, Enrico ; Lanzafame, Salvatore ; Tendi, Elisabetta ; Celeste, Salvatore ; Di Pietro, Cinzia ; Basile, Francesco ; Purrello, Michele. / Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. In: Journal of Molecular Medicine. 2012 ; Vol. 90, No. 12. pp. 1421-1438.
@article{8498c92d43754642901854b6826d30b8,
title = "Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors",
abstract = "The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway has a master control role in various cancer-related biological processes as cell growth, proliferation, differentiation, migration, and apoptosis. It also regulates many transcription factors that control microRNAs (miRNAs) and their biosynthetic machinery. To investigate on the still poorly characterised global involvement of miRNAs within the pathway, we profiled the expression of 745 miRNAs in three colorectal cancer (CRC) cell lines after blocking the pathway with three different inhibitors. This allowed the identification of two classes of post-treatment differentially expressed (DE) miRNAs: (1) common DE miRNAs in all CRC lines after treatment with a specific inhibitor (class A); (2) DE miRNAs in a single CRC line after treatment with all three inhibitors (class B). By determining the molecular targets, biological roles, network position of chosen miRNAs from class A (miR-372, miR-663b, miR-1226*) and class B (miR-92a-1*, miR-135b*, miR-720), we experimentally demonstrated that they are involved in cell proliferation, migration, apoptosis, and globally affect the regulation circuits centred on MAPK/ERK signaling. Interestingly, the levels of miR-92a-1*, miR-135b*, miR-372, miR-720 are significantly higher in biopsies from CRC patients than in normal controls; they also are significantly higher in CRC patients with mutated KRAS than in those with wild-type genotypes (Wilcoxon test, p <0.05): the latter could be a downstream effect of ERK pathway overactivation, triggered by KRAS mutations. Finally, our functional data strongly suggest the following miRNA/target pairs: miR-92a-1*/PTEN-SOCS5; miR-135b*/LATS2; miR-372/TXNIP; miR-663b/CCND2. Altogether, these results contribute to deepen current knowledge on still uncharacterized features of MAPK/ERK pathway, pinpointing new oncomiRs in CRC and allowing their translation into clinical practice and CRC therapy.",
keywords = "Cellular networks, Colorectal cancer, ERK/MAPK pathway, miRNA profile, miRNA protein targets",
author = "Marco Ragusa and Luisa Statello and Marco Maugeri and Alessandra Majorana and Davide Barbagallo and Loredana Salito and Mariangela Sammito and Manuela Santonocito and Rosario Angelica and Andrea Cavallaro and Marina Scalia and Rosario Caltabiano and Giuseppe Privitera and Antonio Biondi and {Di Vita}, Maria and Alessandro Cappellani and Enrico Vasquez and Salvatore Lanzafame and Elisabetta Tendi and Salvatore Celeste and {Di Pietro}, Cinzia and Francesco Basile and Michele Purrello",
year = "2012",
month = "12",
doi = "10.1007/s00109-012-0918-8",
language = "English",
volume = "90",
pages = "1421--1438",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors

AU - Ragusa, Marco

AU - Statello, Luisa

AU - Maugeri, Marco

AU - Majorana, Alessandra

AU - Barbagallo, Davide

AU - Salito, Loredana

AU - Sammito, Mariangela

AU - Santonocito, Manuela

AU - Angelica, Rosario

AU - Cavallaro, Andrea

AU - Scalia, Marina

AU - Caltabiano, Rosario

AU - Privitera, Giuseppe

AU - Biondi, Antonio

AU - Di Vita, Maria

AU - Cappellani, Alessandro

AU - Vasquez, Enrico

AU - Lanzafame, Salvatore

AU - Tendi, Elisabetta

AU - Celeste, Salvatore

AU - Di Pietro, Cinzia

AU - Basile, Francesco

AU - Purrello, Michele

PY - 2012/12

Y1 - 2012/12

N2 - The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway has a master control role in various cancer-related biological processes as cell growth, proliferation, differentiation, migration, and apoptosis. It also regulates many transcription factors that control microRNAs (miRNAs) and their biosynthetic machinery. To investigate on the still poorly characterised global involvement of miRNAs within the pathway, we profiled the expression of 745 miRNAs in three colorectal cancer (CRC) cell lines after blocking the pathway with three different inhibitors. This allowed the identification of two classes of post-treatment differentially expressed (DE) miRNAs: (1) common DE miRNAs in all CRC lines after treatment with a specific inhibitor (class A); (2) DE miRNAs in a single CRC line after treatment with all three inhibitors (class B). By determining the molecular targets, biological roles, network position of chosen miRNAs from class A (miR-372, miR-663b, miR-1226*) and class B (miR-92a-1*, miR-135b*, miR-720), we experimentally demonstrated that they are involved in cell proliferation, migration, apoptosis, and globally affect the regulation circuits centred on MAPK/ERK signaling. Interestingly, the levels of miR-92a-1*, miR-135b*, miR-372, miR-720 are significantly higher in biopsies from CRC patients than in normal controls; they also are significantly higher in CRC patients with mutated KRAS than in those with wild-type genotypes (Wilcoxon test, p <0.05): the latter could be a downstream effect of ERK pathway overactivation, triggered by KRAS mutations. Finally, our functional data strongly suggest the following miRNA/target pairs: miR-92a-1*/PTEN-SOCS5; miR-135b*/LATS2; miR-372/TXNIP; miR-663b/CCND2. Altogether, these results contribute to deepen current knowledge on still uncharacterized features of MAPK/ERK pathway, pinpointing new oncomiRs in CRC and allowing their translation into clinical practice and CRC therapy.

AB - The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway has a master control role in various cancer-related biological processes as cell growth, proliferation, differentiation, migration, and apoptosis. It also regulates many transcription factors that control microRNAs (miRNAs) and their biosynthetic machinery. To investigate on the still poorly characterised global involvement of miRNAs within the pathway, we profiled the expression of 745 miRNAs in three colorectal cancer (CRC) cell lines after blocking the pathway with three different inhibitors. This allowed the identification of two classes of post-treatment differentially expressed (DE) miRNAs: (1) common DE miRNAs in all CRC lines after treatment with a specific inhibitor (class A); (2) DE miRNAs in a single CRC line after treatment with all three inhibitors (class B). By determining the molecular targets, biological roles, network position of chosen miRNAs from class A (miR-372, miR-663b, miR-1226*) and class B (miR-92a-1*, miR-135b*, miR-720), we experimentally demonstrated that they are involved in cell proliferation, migration, apoptosis, and globally affect the regulation circuits centred on MAPK/ERK signaling. Interestingly, the levels of miR-92a-1*, miR-135b*, miR-372, miR-720 are significantly higher in biopsies from CRC patients than in normal controls; they also are significantly higher in CRC patients with mutated KRAS than in those with wild-type genotypes (Wilcoxon test, p <0.05): the latter could be a downstream effect of ERK pathway overactivation, triggered by KRAS mutations. Finally, our functional data strongly suggest the following miRNA/target pairs: miR-92a-1*/PTEN-SOCS5; miR-135b*/LATS2; miR-372/TXNIP; miR-663b/CCND2. Altogether, these results contribute to deepen current knowledge on still uncharacterized features of MAPK/ERK pathway, pinpointing new oncomiRs in CRC and allowing their translation into clinical practice and CRC therapy.

KW - Cellular networks

KW - Colorectal cancer

KW - ERK/MAPK pathway

KW - miRNA profile

KW - miRNA protein targets

UR - http://www.scopus.com/inward/record.url?scp=84884211395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884211395&partnerID=8YFLogxK

U2 - 10.1007/s00109-012-0918-8

DO - 10.1007/s00109-012-0918-8

M3 - Article

VL - 90

SP - 1421

EP - 1438

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 12

ER -